Target intelligence / Profile preview

E3 ubiquitin-protein ligase TRIM31 (TRIM31)

Target
TRIM31
Molecular classification
E3 ubiquitin ligase, Enzyme, Tripartite motif (TRIM) family protein, RING-type E3 ubiquitin-protein ligase
01

Overview

E3 ubiquitin-protein ligase TRIM31 (TRIM31) is an enzyme of the tripartite motif (TRIM) family, containing RING, B-box, and coiled-coil domains. It mediates ubiquitin-dependent proteasomal degradation of specific substrates and plays a crucial role in the regulation of the immune response, inflammation (notably as a negative regulator of the NLRP3 inflammasome), hematopoietic stem cell quiescence, cell cycle control, and autophagy. Abnormal TRIM31 expression or function is associated with cancer, infection, inflammatory disorders, cardiovascular and metabolic diseases. The protein’s dualistic role in cancer—as either a tumor suppressor or promoter—depends on cellular context and the specific signaling pathways involved, notably impacting p53, mTORC1, PI3K-AKT, NF-κB, and Wnt/β-catenin. Its critical regulatory functions and disease associations position TRIM31 as a potential, yet complex, therapeutic target.

Other names
Tripartite motif-containing protein 31C6orf13HCG1HCGIRNFTripartite motif containing 31
02

Mechanism of action

Promotes ubiquitination and proteasomal degradation of target proteins (such as NLRP3, p53, CDK8). Regulates K48- and K63-linked ubiquitination pathways.

03

Biological functions

Ubiquitin-mediated protein degradationRegulation of immune response (innate immunity)Regulation of inflammationRegulation of hematopoietic stem cell homeostasisAutophagyCell cycle regulationTumor suppression and promotion (context dependent)
04

Disease associations

CancerInflammationInfection (antiviral immunity)Cardiovascular diseaseNeurodegenerationHematological disordersOther (such as nonalcoholic fatty liver disease and hypertensive nephropathy)
05

Safety considerations

Context-dependent dual role: can act as either a tumor promoter or suppressor depending on cellular context, raising concerns for targeted therapyIts broad regulatory effects on immune and inflammatory pathways suggest possible off-target consequences, including immunosuppression or excessive inflammation upon modulation
06

Biomarkers

Altered TRIM31 expression linked to various tumors and some inflammatory conditions may serve as a potential biomarker

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase TRIM31 (TRIM31).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM31 (TRIM31).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call